Non-antibiotic strategies for the prevention/treatment of Clostridium difficile infection

Bibliography

• Hall J, O'Toole E. Intestinal flora in newborn infants with description of a new pathogenic organism Bacillus dificilis. Am J Dis Child 1935;49:390-402
   Google Scholar
• Rifkin GD, Fekety FR, Silva J Jr. Antibiotic-induced colitis implication of a toxin neutralised by Clostridium sordellii antitoxin. Lancet 1977;2(8048):1103-6
   PubMed Web of Science ®Google Scholar
• Bartlett JG, Onderdonk AB, Cisneros RL, et al. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis 1977;136(5):701-5
   PubMed Web of Science ®Google Scholar
• Larson HE, Price AB, Honour P, et al. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1978;1(8073):1063-6
   PubMed Web of Science ®Google Scholar
• Monaghan T, Boswell T, Mahida YR. Recent advances in Clostridium difficile-associated disease. Gut 2008;57(6):850-60
   PubMed Web of Science ®Google Scholar
• Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Eng J Med 2002;346(5):334-9
   PubMed Web of Science ®Google Scholar
• Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005;5(9):549-57
   PubMed Web of Science ®Google Scholar
• Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Eng J Med 1994;330(4):257-62
   PubMed Web of Science ®Google Scholar
• Fekety R, Kim KH, Brown D, et al. Epidemiology of antibiotic-associated colitis; isolation of Clostridium difficile from the hospital environment. Am J Med 1981;70(4):906-8
   PubMed Web of Science ®Google Scholar
• Kim KH, Fekety R, Batts DH, et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 1981;143(1):42-50
   PubMed Web of Science ®Google Scholar
• Wullt M, Odenholt I, Walder M. Activity of three disinfectants and acidified nitrite against Clostridium difficile spores. Infect Control Hosp Epidemiol 2003;24(10):765-8
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Fawley WN, Wigglesworth N, et al. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J Hosp Infect 2003;54(2):109-14
   PubMed Web of Science ®Google Scholar
• Taylor NS, Thorne GM, Bartlett JG. Comparison of two toxins produced by Clostridium difficile. Infect Immun 1981;34(3):1036-43
   PubMed Web of Science ®Google Scholar
• Just I, Fritz G, Aktories K, et al. Clostridium difficile toxin B acts on the GTP-binding protein Rho. J Biol Chem 1994;269(14):10706-12
   PubMedGoogle Scholar
• Dillon ST, Rubin EJ, Yakubovich M, et al. Involvement of Ras-related Rho proteins in the mechanisms of action of Clostridium difficile toxin A and toxin B. Infect Immun 1995;63(4):1421-6
   PubMed Web of Science ®Google Scholar
• Lyerly DM, Lockwood DE, Richardson SH, et al. Biological activities of toxins A and B of Clostridium difficile. Infect Immun 1982;35(3):1147-50
   PubMed Web of Science ®Google Scholar
• Lyerly DM, Saum KE, MacDonald DK, et al. Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun 1985;47(2):349-52
   PubMed Web of Science ®Google Scholar
• Alfa MJ, Kabani A, Lyerly D, et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000;38(7):2706-14
   PubMed Web of Science ®Google Scholar
• Perelle S, Gibert M, Bourlioux P, et al. Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196. Infect Immun 1997;65(4):1402-7
   PubMed Web of Science ®Google Scholar
• Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40(11):1586-90
   PubMed Web of Science ®Google Scholar
• Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40(11):1591-7
   PubMed Web of Science ®Google Scholar
• Shin JW, Yong D, Kim MS, et al. Sudden increase of vancomycin-resistant enterococcal infections in a Korean tertiary care hospital: possible consequences of increased use of oral vancomycin. J Infect Chemother 2003;9(1):62-7; discussion 104-5
   PubMedGoogle Scholar
• Wilcox MH, Freeman J. Epidemic Clostridium difficile. N Eng J Med 2006;354(11):1199-203; author reply 203
   PubMedGoogle Scholar
• Available from: www.hpa.org.uk
   Google Scholar
• Centers for Disease Control. Severe Clostridium difficile-associated disease in populations previously at low risk: four states, 2005. MMWR Morb Mortal Wkly Rep 2005;54:1201-6
   PubMedGoogle Scholar
• Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. Cmaj 2005;173(9):1037-42
   PubMed Web of Science ®Google Scholar
• McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Eng J Med 2005;353(23):2433-41
   PubMed Web of Science ®Google Scholar
• Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366(9491):1079-84
   PubMed Web of Science ®Google Scholar
• Akerlund T, Persson I, Unemo M, et al. Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1. J Clin Microbiol 2008;46(4):1530-3
   PubMed Web of Science ®Google Scholar
• Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41(9):1254-60
   PubMed Web of Science ®Google Scholar
• Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006;(12 Suppl)6:2-18
   Google Scholar
• McMaster-Baxter NL, Musher DM. Clostridium difficile: recent epidemiologic findings and advances in therapy. Pharmacotherapy 2007;27(7):1029-39
   PubMedGoogle Scholar
• Surowiec D, Kuyumjian AG, Wynd MA, et al. Past, present, and future therapies for Clostridium difficile-associated disease. Ann Pharmacother 2006;40(12):2155-63
   PubMed Web of Science ®Google Scholar
• Ryan ET, Butterton JR, Smith RN, et al. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect Immun 1997;65(7):2941-9
   PubMed Web of Science ®Google Scholar
• Torres JF, Lyerly DM, Hill JE, et al. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun 1995;63(12):4619-27
   PubMed Web of Science ®Google Scholar
• Thomas WD Jr. Immunization against Clostridium difficile disease. US2007231336
   Google Scholar
• Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005;128(3):764-70
   PubMed Web of Science ®Google Scholar
• Giannasca PJ, Zhang ZX, Lei WD, et al. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun 1999;67(2):527-38
   PubMed Web of Science ®Google Scholar
• Ward SJ, Douce G, Figueiredo D, et al. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect Immun 1999;67(5):2145-52
   PubMed Web of Science ®Google Scholar
• Wilkins TD, et al. Recombinant toxin A and toxin B protein carrier for polysaccharide conjugate vaccines. US2005202042
   Google Scholar
• Gardiner DF. Codon-optimized DNA molecules encoding the receptor binding domains of Clostridium difficile toxins A and B, and methods of use thereof. WO2007146139
   Google Scholar
• Kink JA, Williams JA. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 1998;66(5):2018-25
   PubMed Web of Science ®Google Scholar
• Lyerly DM, Bostwick EF, Binion SB, et al. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun 1991;59(6):2215-8
   PubMedGoogle Scholar
• Warny M, Fatimi A, Bostwick EF, et al. Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut 1999;44(2):212-7
   PubMed Web of Science ®Google Scholar
• van Dissel JT, de Groot N, Hensgens CM, et al. Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbial 2005;54(Pt 2):197-205
   PubMed Web of Science ®Google Scholar
• Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997;41(3):366-70
   PubMed Web of Science ®Google Scholar
• Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001;357(9251):189-93
   PubMed Web of Science ®Google Scholar
• Meyer M. Oral use of specific antibodies for intestinal health. US2007154484
   Google Scholar
• Simon MR. Human secretory IgA for the treatment of Clostridium difficile associated diseases. US2008145420
   Google Scholar
• Simon MR. Synthesis of human secretory IgM and the treatment of Clostridium difficile associated diseases herewith. US2008145370
   Google Scholar
• Drudy D, Calabi E, Kyne L, et al. Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol Med Microbiol 2004;41(3):237-42
   PubMed Web of Science ®Google Scholar
• Calabi E, Calabi F, Phillips AD, et al. Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect Immun 2002;70(10):5770-78
   PubMed Web of Science ®Google Scholar
• Windle HJ, et al. Clostridium difficile vaccine. US2007065446
   Google Scholar
• O'Brien JB, McCabe MS, Athie-Morales V, et al. Passive immunisation of hamsters against Clostridium difficile infection using antibodies to surface layer proteins. FEMS Microbiol Lett 2005;246(2):199-205
   PubMed Web of Science ®Google Scholar
• Ni Eidhin DB, O'Brien JB, McCabe MS, et al. Active immunization of hamsters against Clostridium difficile infection using surface-layer protein. FEMS Immunol Med Microbiol 2008;52(2):207-18
   PubMedGoogle Scholar
• Corthier G, Muller MC, Wilkins TD, et al. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun 1991;59(3):1192-5
   PubMed Web of Science ®Google Scholar
• Babcock GJ, Broering TJ, Hernandez HJ, et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 2006;74(11):6339-47
   PubMed Web of Science ®Google Scholar
• Ambrosino D, Babcock GJ, Broering T, et al. Antibodies against Clostridium difficile toxins and uses thereof. WO2006121422
   Google Scholar
• von Eichel-Streiber C, Moos M. Amino acid sequences for therapeutic and prophylactic use against diseases due to Clostridium difficile toxins. US2004137601
   Google Scholar
• Sutherland A. Inhibitory analogues to block receptors for microbial pathogenic determinants. WO2006038007
   Google Scholar
• Reineke J, Tenzer S, Rupnik M, et al. Autocatalytic cleavage of Clostridium difficile toxin B. Nature 2007;446(7134):415-9
   PubMed Web of Science ®Google Scholar
• von Eichel-Streiber C, et al. Medicament for LCT poisoning. WO2008014733
   Google Scholar
• Burnie JP, et al. Treatment of bacterial infections. WO2006003426
   Google Scholar
• Krivan HC, Clark GF, Smith DF, et al. Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun 1986;53(3):573-81
   PubMed Web of Science ®Google Scholar
• Nilsson UJ, Heerze LD, Liu YC, et al. Immobilization of reducing sugars as toxin binding agents. Bioconjug Chem 1997;8(4):466-71
   PubMed Web of Science ®Google Scholar
• Castagliuolo I, LaMont JT, Qiu B, et al. A receptor decoy inhibits the enterotoxic effects of Clostridium difficile toxin A in rat ileum. Gastroenterology 1996;111(2):433-8
   PubMed Web of Science ®Google Scholar
• Heerze LD, Armstrong GD. Treatment antibiotic-associated diarrhea. WO951628.
   Google Scholar
• Charmot D. Toxin binding compositions. US2006099169
   Google Scholar
• Ariano RE, Zhanel GG, Harding GK. The role of anion-exchange resins in the treatment of antibiotic-associated pseudomembranous colitis. CMAJ 1990;142(10):1049-51
   PubMed Web of Science ®Google Scholar
• Frapaise X, Anderson K. Use of adsorbent carbon microspheres to treat intestinal bacterial infections. US2008089942
   Google Scholar
• Braunlin W, Xu Q, Hook P, et al. Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophys J 2004;87(1):534-9
   PubMed Web of Science ®Google Scholar
• Kurtz CB, Cannon EP, Brezzani A, et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother 2001;45(8):2340-7
   PubMed Web of Science ®Google Scholar
• Chancellor-Adams T, et al. Poly (potassium and sodium styrene sulfonate) its manufacture and its uses. US2007053865
   Google Scholar
• Ho C et al. Polystyrene sulfonate polymer tablets, their preparation and use. WO2008030512
   Google Scholar
• Louie TJ, Peppe J, Watt CK, et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43(4):411-20
   PubMed Web of Science ®Google Scholar
• Hinkson PL, Dinardo C, DeCiero D, et al. Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile. Antimicrob Agents Chemother 2008;52(6):2190-5
   PubMed Web of Science ®Google Scholar
• Macfarlane GT, Cummings JH. Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health? BMJ 1999;318(7189):999-1003
   PubMed Web of Science ®Google Scholar
• McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271(24):1913-8
   PubMed Web of Science ®Google Scholar
• Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005;40(11):1625-34
   PubMed Web of Science ®Google Scholar
• Cortesy-Theulaz I, et al. Moderating the effect of endotoxins. US2006292171
   Google Scholar
• Dieckgraefe B. High affinity ligands bind to Clostridium difficile toxin A. US20067249524
   Google Scholar
• Tucker KD, Wilkins TD. Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y. Infect Immun 1991;59(1):73-8
   PubMed Web of Science ®Google Scholar
• Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008;46(Suppl 1):S32-42
   PubMed Web of Science ®Google Scholar
• Johal SS, Lambert CP, Hammond J, et al. Colonic IgA producing cells and macrophages are reduced in recurrent and non-recurrent Clostridium difficile associated diarrhoea. J Clin Pathol 2004;57(9):973-9
   PubMed Web of Science ®Google Scholar
• Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004;53(5):882-4
   PubMed Web of Science ®Google Scholar
• Gerding DN, Muto CA, Owens RC Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008;46(Suppl 1):S43-9
   PubMed Web of Science ®Google Scholar